Oxford’s COVID-19 vaccine will be combined with human adenoviral vector type Ad26 component of Russia’s Sputnik V jab in the new clinical trials to study the possibility of boosting their vaccine’s efficacy, according to a release issued by the Russian Direct Investment Fund (RDIF). The trial is set to initiate by the end of 2020.
Sputnik V combines two different human adenoviral vectors for a prime and a boost immunization which provides for a stronger and longer-term immune response compared to vaccines using the same component for both inoculations. The vaccine was discovered by the researchers at Gamaleya Center.
The RDIF and Gamaleya Institute had offered AstraZeneca to use one of the two components (human adenoviral vectors) of the Sputnik V vaccine in its clinical trial, following the high efficacy data found during preliminary studies.
“The decision by AstraZeneca to carry out clinical trials using one of two vectors of Sputnik V in order to increase its own vaccine’s efficacy is an important step towards uniting efforts in the fight against the pandemic. We welcome the beginning of this new stage of cooperation between vaccine producers. We are determined to develop this partnership in the future and to start joint production after the new vaccine demonstrates its efficacy in the course of clinical trials.” said Kirill Dmitriev, CEO of the RDIF.
Russia would jointly produce the innovative vaccine if it is proven to be effective, said the release.